Chongqing Lummy Pharmaceutical
Chongqing Lummy Pharmaceutical Co., Ltd. engages in the research and development, manufacture, and sale of pharmaceutical products in China. It provides anti-tumor, anti-inflammatory, antibacterial, digestive, anti-virus, blood system, cardiovascular system, acid-base balance nutritional medicine, endocrine system drugs, tumor adjuvant medication, antifungal, and opioid receptor antagonists. Chon… Read more
Chongqing Lummy Pharmaceutical (300006) - Total Liabilities
Latest total liabilities as of September 2025: CN¥910.32 Million CNY
Based on the latest financial reports, Chongqing Lummy Pharmaceutical (300006) has total liabilities worth CN¥910.32 Million CNY as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Chongqing Lummy Pharmaceutical - Total Liabilities Trend (2006–2024)
This chart illustrates how Chongqing Lummy Pharmaceutical's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Chongqing Lummy Pharmaceutical Competitors by Total Liabilities
The table below lists competitors of Chongqing Lummy Pharmaceutical ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Rogers Sugar Inc
PINK:RSGUF
|
USA | $668.39 Million |
|
Shen Ma Industry Co Ltd
SHG:600810
|
China | CN¥19.66 Billion |
|
Chengdu Galaxy Magnets
SHE:300127
|
China | CN¥99.62 Million |
|
Shanghai Xinpeng Industry Co Ltd
SHE:002328
|
China | CN¥1.82 Billion |
|
Drägerwerk AG & Co. KGaA
PINK:DGWPF
|
USA | $1.52 Billion |
|
Topdanmark AS
PINK:TPDKY
|
USA | $18.45 Billion |
|
EQ Resources Ltd
AU:EQR
|
Australia | AU$152.98 Million |
Liability Composition Analysis (2006–2024)
This chart breaks down Chongqing Lummy Pharmaceutical's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.04 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.50 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.33 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Chongqing Lummy Pharmaceutical's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Chongqing Lummy Pharmaceutical (2006–2024)
The table below shows the annual total liabilities of Chongqing Lummy Pharmaceutical from 2006 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥972.47 Million | +26.51% |
| 2023-12-31 | CN¥768.71 Million | -11.64% |
| 2022-12-31 | CN¥870.02 Million | +21.74% |
| 2021-12-31 | CN¥714.65 Million | -62.70% |
| 2020-12-31 | CN¥1.92 Billion | +3.71% |
| 2019-12-31 | CN¥1.85 Billion | +30.42% |
| 2018-12-31 | CN¥1.42 Billion | +39.24% |
| 2017-12-31 | CN¥1.02 Billion | +25.63% |
| 2016-12-31 | CN¥809.85 Million | -42.68% |
| 2015-12-31 | CN¥1.41 Billion | +15.15% |
| 2014-12-31 | CN¥1.23 Billion | +16.14% |
| 2013-12-31 | CN¥1.06 Billion | +48.12% |
| 2012-12-31 | CN¥713.21 Million | +69.48% |
| 2011-12-31 | CN¥420.81 Million | +30.52% |
| 2010-12-31 | CN¥322.42 Million | +150.82% |
| 2009-12-31 | CN¥128.55 Million | -1.70% |
| 2008-12-31 | CN¥130.77 Million | +22.47% |
| 2007-12-31 | CN¥106.78 Million | +75.86% |
| 2006-12-31 | CN¥60.72 Million | -- |